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In healthy circumstances the immune system coordinates tissue repair responses in a tight bal-
ance that entails efficient inflammation for removal of potential threats, proper wound closure,
and regeneration to regain tissue function. Pathological conditions, continuous exposure to nox-
ious agents, and even ageing can dysregulate immune responses after injury. This dysregulation
can lead to a chronic repair mechanism known as fibrosis. Alterations in wound healing can occur
in many organs, but our focus lies with the lung as it requires highly regulated immune and repair
responses with its continuous exposure to airborne threats. Dysregulated repair responses can
lead to pulmonary fibrosis but the exact reason for its development is often not known. Here, we
review the diversity of innate immune cells of myeloid origin that are involved in tissue repair and
we illustrate how these cell types can contribute to the development of pulmonary fibrosis.More-
over, we briefly discuss the effect of age on innate immune responses and therefore on wound
healing and we conclude with the implications of current knowledge on the avenues for future
research.
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1 INTRODUCTION
Tissue repair is an essential process that allows the replacement of
damaged cells and the restoration of organ function, which is key for
survival (Wynn, 2007). When a tissue is harmed, the immune system
acts to contain potential threats and to re-establish function and
structure of the affected organ (Li, Chen, & Kirsner, 2007). Tissue
damage can be caused by microbial infections, the exposure to toxic
compounds, burns, and mechanical trauma, among other factors.
Although the details of the immune events might vary depending on
thenature of the injury, in general thephases leading to tissue recovery
are rather conserved. These phases are clotting, inflammation, tissue
repair, and resolution and return to tissue homeostasis (see Fig. 1)
(Li et al., 2007). The daily exposure to airborne microorganisms and
particles makes the lung a susceptible target for tissue injury, which
is why evolution provided the mammalian lung with an elaborate
immune system (Nicod, 2005). The optimal function of the lung relies
on a regulated balance between immune responses, tissue repair,
and tissue function, accommodating protection from infection and
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injury without considerably affecting tissue structure and function.
This makes the lung an interesting immune center and therefore here
we focus on the lung as the model organ to exemplify the general
steps associated with typical tissue injuries and the alterations of
innate immune responses in wound healing and fibrosis development.
Whenever available we include data from clinical studies involving
patients with pulmonary fibrosis of either unknown origin (idiopathic
pulmonary fibrosis or IPF) or of known origin and from well-known
mousemodels of pulmonary fibrosis.
2 TISSUE REPAIR AND FIBROSIS
DEVELOPMENT
2.1 Phases of tissue repair
The events associated with acute injury involve the activity of the
innate part of the immune system (Fig. 1). Infiltration of pathologi-
cal microorganisms or destruction of tissue results in expression of
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F IGURE 1 Phases of tissue repair in the context of myeloid cells. (1) Clotting (top right) is the first step after injury takes place. Damage to
alveolar epithelial cells (AEC) leads to the aggregation of erythrocytes and platelets that form a blood clot to contain spreading of the damage.
The destruction of the tissue causes release of damage-associated molecular patterns (DAMPs), or allows the entrance of microorganisms and
thereby pathogen-associatedmolecular patterns (PAMPs). Local cells such as dendritic cells, macrophages, and AECs are activated by DAMPs and
PAMPs through toll-like receptors (TLRs) and protease-activated receptors (PARs) and produce the first round of pro-inflammatory mediators.
(2) Inflammation (bottom right) involves the infiltration of neutrophils and monocytes that respond to the pro-inflammatory stimuli that were
producedby resident lung cells. Phagocytes such as neutrophils andmacrophages remove tissue debris andpotentially threatening particles. In this
pro-inflammatory environment, monocytes and resident macrophages can differentiate intoM1macrophages that further promote inflammatory
responses by the production of pro-inflammatory mediators such as IL-6 and TNF-𝛼. (3) Repair (bottom left) is the phase in which inflammatory
responses subside and turn into repair responses through the effects of anti-inflammatory and pro-repair cytokines such as IL-10 andTGF-𝛽 . In this
stage fibrocytesenter the tissueanddifferentiate into fibroblasts thatproliferate and turn into themorecontractilemyofibroblasts.Myofibroblasts
produce extracellular matrix (ECM) to close the open wound and form a scar. M2 macrophages predominate in this stage and produce mediators
that contribute to the proliferation of fibroblasts and the deposition of ECM. (4) Resolution (top left) refers to the last phase in tissue repair inwhich
excess ECM is degraded tomake space for new cells. At the end of this stage the tissue has regained its structure and function
molecular patterns that alarm the immune system about danger. In
the case of an infection these molecules are known as pathogen-
associated molecular patterns (PAMPs), and in the case of destruc-
tionof tissue they are knownasdamage-associatedmolecular patterns
(DAMPs) (Davidovich, Kearney, & Martin, 2014; Medzhitov, 2007).
DAMPs are usually molecules that are found in the intracellular milieu
under normal conditions and thus, once found in the extracellular
space, are a sign of tissue damage (e.g., heme and thrombin) (Chen &
Nuñez, 2010). The release of DAMPs and PAMPSwill activate resident
cells such as macrophages, dendritic cells (DCs), mast cells, epithe-
lial cells, natural killer cells and innate lymphoid cells through their
sensors of these molecules, i.e., toll-like receptors (TLRs). Their acti-
vation will result in the production of other soluble mediators, such as
histamine, interleukins (IL, e.g. IL-1 and IL-33), andother cytokines, and
chemokines (e.g., macrophagemigration inhibitory factor [MIF], CCL2,
and CXCL8, which function as an alarm to activate and recruit other
cells of the immune system to the affected area (Hussell & Bell, 2014;
Julier, Park, Briquez,&Martino, 2017;Kurowska-Stolarskaet al., 2009;
Zimmermann, Trautwein, & Tacke, 2012).
The release of DAMPs and PAMPs occurs in parallel with activa-
tion of the coagulation cascade that is initiated by damage to blood
vessels. This is the beginning of the clotting phase. Clotting prevents
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blood loss and protects the open wound from further exposure. Clot-
ting alsohas adirect effect on resident tissuemacrophages and leads to
their activation through exposure to free heme from coagulation and
through thrombin-induced cleavage of protease-activated receptors
found on macrophages and other resident cells (Asokananthan et al.,
2002; Colognato et al., 2003; Dutra & Bozza, 2014; Mercer & Cham-
bers, 2013; Minutti, Knipper, Allen, & Zaiss, 2016). The second phase,
known as inflammation, beginswith infiltration of recruited leukocytes
to thewound. These leukocytes aremostly neutrophils andmonocytes
that phagocytosemicroorganisms, dying cells and cell debris, thus pre-
venting the spread of damage and pathogens (Dale, Boxer, & Conrad
Liles, 2008). Some of these monocytes differentiate into macrophages
that initially also promote inflammation. Eventually the inflammation
phase declines and progresses towards a repair phase, in which anti-
inflammatory and pro-repair cytokines such as IL-10 and transforming
growth factor beta (TGF-𝛽) activate myofibroblasts. This leads to the
deposition of extracellular matrix (ECM) for formation of scar tissue
that serves as a temporary protection and scaffold for newly formed
tissue (Boorsma, Draijer, & Melgert, 2013). At this point parenchymal
cells start regrowing, which sets the beginning of the last phase known
as resolutionand return tohomeostasis.During this phase, excessECM
is removed by macrophages and fibroblasts through the production
of proteases such as cathepsins, matrix metalloproteinases (MMPs),
and plasmin, and parenchymal cell growth is stimulated for the re-
establishment of tissue structure and function (Adhyatmika, Putri, Bel-
jaars, & Melgert, 2015; Boorsma et al., 2013). The duration of each
of these phases is tissue-dependent and may be further influenced by
external conditions and individual factors (Guo &Dipietro, 2010).
Wound healing in adult mammals can only restore structure and
function to some degree as we have a limited regenerative capacity.
Only our liver and skeletal muscles can recover from significant tis-
sue damage (Corona et al., 2013; Michalopoulos, 2013; Taub, 2004).
Mammalian embryos, on theother hand, are capable of scar-free repair
but they lose this ability soon after birth (Ferguson & O'Kane, 2004;
Kishi, Okabe, Shimizu, & Kubota, 2012; Porrello et al., 2011). It has
been suggested that the complexity and specialization of the immune
system in animals is inversely correlated to the ability for tissue regen-
eration, as smaller animals like amphibians can regenerate completely
severed limbs (Godwin&Rosenthal, 2014;Godwin, Pinto, &Rosenthal,
2016; Julier et al., 2017). Studies in frogs suggest that the adaptive
immune system may be involved in the limitation of tissue regenera-
tion (Mescher et al., 2007). Other amphibians, young frogs, and new-
bornhumans either lack or have immature adaptive immunity andhave
greater regenerative potential (Godwin & Rosenthal, 2014; Mescher
et al., 2007). This suggests that the key to scar-free healing and active
regeneration in adult mammals relies on the innate immune system.
2.2 Dysregulatedwound healing in the
pathogenesis of fibrosis
Despite the limited capacity for regeneration, healthy individuals are
capable of healing in most situations and eventually tissue home-
ostasis is restored. However, dysregulation of any of the cells or
stages of wound healing or continuous repetitive injury could lead to
pathological outcomes such as cancer, tissue destruction, and/or fibro-
sis. Interestingly, repetitive exposure to the same harmful agent does
not always lead to the same outcome in all individuals. Such is the case
for cigarette smoke exposure, which does not always lead to a patho-
logical condition but it has been associated with the development of
lung cancer, chronic obstructive pulmonary disease (COPD), and pul-
monary fibrosis (Jindal et al., 2006; Lubin et al., 1984;Madan,Matalon,
& Vivero, 2015). This variability in wound healing outcomes is partly
due to the genetic and epigenetic background of each individual and
other intrinsic factors such as age, gender, comorbidities, and many
other factors (reviewed byGuo&Dipietro, 2010). Age in particular has
a great influence on the healing response, as many components of the
immune system change over time and the response to insults tends to
be altered (reviewed by Boe, Boule, & Kovacs, 2016). This is partly the
reason why some diseases such as emphysema and pulmonary fibrosis
mostly develop at older age.
Pulmonary fibrosis can develop as an end stage disease in many
other types of disorders, such as scleroderma, viral infections, disease
caused by exposure to harmful substances or drugs (such as silicosis
induced by exposure to silica), but often its cause is unknown (IPF)
(Wynn, 2011). The fibrosis is caused by a dysregulation in wound heal-
ing responses and the subsequent accumulation of ECM, followed by
changes in lung structure that lead to organmalfunction andultimately
lethal respiratory failure (Camelo, Dunmore, Sleeman, & Clarke, 2014;
Spagnolo, Maher, & Richeldi, 2015;Wynn, 2011).
Once fibrosis develops, there are few available treatment options.
In recent clinical trials, pirfenidone, nintedanib, and N-acetylcysteine
have been shown to be effective in reducing the functional decline
and disease progression in pulmonary fibrosis (Staitieh, Renzoni, &
Veeraraghavan, 2015). However, neither pirfenidone nor nintedanib
nor N-acetylcysteine is a cure for the disease and most patients con-
tinue to progress despite treatment. Therefore the average survival
time after diagnosis is only 3−5 years (Spagnolo et al., 2015).
The pathogenesis of pulmonary fibrosis is usually characterized
by injury to alveolar epithelial cells, recruitment and activation of
(myo)fibroblasts, and subsequent production of ECM, and the dys-
regulated activity of macrophages (Boorsma et al., 2013; Kolahian,
Fernandez, Eickelberg, & Hartl, 2016; Spagnolo et al., 2015; Wynn,
2011). Fibroblasts hyperproliferate in the fibrotic lung forming what is
known as fibrotic foci, which are thought to represent points of injury
(Knudsen, Ruppert, & Ochs, 2017). In fibrosis, fibroblasts differenti-
ate into more contractile and apoptosis-resistant myofibroblasts pro-
moting the fibrotic process. These two types of cells produce imma-
ture forms of collagen and other ECM proteins that promote a pro-
repair macrophage polarization (M2), which in turn produces CCL18
that induces fibroblast activation andmore ECMproduction (Kolahian
et al., 2016; Prasse et al., 2006). This is one of themany examples of cell
interactions that create a profibrotic vicious circle that is probably pro-
moting fibrosis progression. A summary of the processes playing a role
in the pathogenesis of pulmonary fibrosis is depicted in Figure 2.
Although cigarette smoke exposure can contribute to pulmonary
fibrosis, the nature of the initial injury is not always known, particu-
larly in IPF (Madan et al., 2015). Moreover, it is also unclear why the
lung is unable to restore tissue homeostasis and instead continues the
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F IGURE 2 Pathophysiology of pulmonary fibrosis in the context of myeloid cells. The pathogenesis of pulmonary fibrosis is characterized by
an exaggerated repair response to lung injury. These alterations in repair responses include proliferation of fibroblasts in the area of the injury and
differentiation towards myofibroblasts that can form fibroblast foci. Dendritic cells accumulate in fibroblast foci in an immature form due to the
influence of fibroblasts, which decreases T cell activation and proliferation. The predominant Th2 cytokine profile (e.g., IL-4, IL-13), produced by
mast cells among others, promotes the polarization of macrophages towards an M2 phenotype. In turn, M2 macrophages produce soluble medi-
ators such as TGF-𝛽 and CCL8 that lead to fibroblast proliferation and to their differentiation into myofibroblasts and subsequent production of
extracellular matrix (ECM). Moreover, deposition of ECM stimulates CCL8 production by alveolar macrophages resulting in a profibrotic vicious
cycle. High numbers of neutrophils in fibrotic lung tissue contribute to the fibrotic process by perpetuating tissue damage and epithelial destruc-
tion via the production of elastase and possibly also byNETosis. High percentages of circulating fibrocytes are characteristic of pulmonary fibrosis.
These circulating fibrocytes enter lung tissue and develop into fibroblasts that in the fibrotic environment differentiate into myofibroblasts. Addi-
tionally, fibrocytes contribute to the fibrotic process by producing TGF-𝛽 and other mediators that contribute to the redundant and uncontrolled
pro-repair environment of the fibrotic lung
repair process to the point of turning into fibrosis. It is possible, how-
ever, that epigenetic regulations following repetitive injury may be the
cause of the change from repair to fibrosis. Most types of fibrosis do
not present with an inflammatory component, but it is hypothesized
that fibrosis is initiated with a lung injury and a subsequent inflamma-
tory response, whichwill eventually be altered and skewed towards an
extreme pro-repair response (Wynn, 2011). Thismay explainwhy anti-
inflammatory and immunosuppressive agents were shown to be inef-
fective for patients with pulmonary fibrosis, because at the moment
of diagnosis they are usually beyond inflammation and suffering from
severe fibrotic disease (Staitieh et al., 2015). As mentioned before,
due to the impressive scar-free tissue repair of small amphibians lack-
ing adaptive immunity, we believe that the key to proper healing of
fibrosis relies on the innate immune system, i.e., cells of myeloid ori-
gin. Therefore, understanding how thesemyeloid cells act during func-
tional wound healing versus fibrotic healing can provide an insight into
future therapeutic measures.
3 MYELOID CELLS IN TISSUE REPAIR AND
FIBROSIS IN THE LUNG
The term “myeloid,” from the ancient Greek Muelos- (marrow) and
-eides (likeness), refers to cells that resemble those in bone marrow.
In a hematopoietic context, the myeloid line actually refers to those
cells that in fact originate from bone marrow progenitors and form
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the granulocytic and monocytic lineages, but not the lymphoid lin-
eage (Kawamoto & Minato, 2004). Myeloid progenitors can develop
into innate immune cells that compose the primary response against
microorganisms and injury. Therefore, myeloid cells have been the
focus of interest in studies of wound healing and fibrosis development
(Doulatov, Notta, Laurenti, & Dick, 2012; Kawamoto &Minato, 2004).
Myeloid cells can be further classified by the presence or absence
of granules, observed after leukocyte staining. They are divided into
granulocytes, i.e., neutrophils, mast cells, eosinophils, and basophils,
and agranulocytes ormonocytic cells, i.e., monocytes and their derived
cells, macrophages, DCs, and fibrocytes (Kay, 2016). We shall use
this classification to present these cell types and their involvement in
wound healing and fibrosis.
3.1 Monocytes andmonocyte-derived cells
3.1.1 Monocytes
Monocytes are mononuclear leukocytes derived from common
monocyte progenitor cells in bone marrow after stimulation with
macrophage colony stimulating factor (M-CSF) (Auffray, Sieweke,
& Geissmann, 2009; Hettinger et al., 2013). Once in blood, mono-
cytes account for 10% and 4% of leukocytes in human and mouse,
respectively (Das et al., 2015).
During tissue injury, monocytes are commonly known to arrive at
the area of injury right after neutrophils. Older studies estimated that
monocytes arrive 1−3 days after neutrophils, but more recent inves-
tigations have found that monocytes can arrive at an injured tissue
within the first hours after tissue damage simultaneously with neu-
trophil infiltration (Dal-Secco et al., 2015;Gurtner,Werner, Barrandon,
& Longaker, 2008; Rodero et al., 2014). To be noted, these results origi-
nate from studies usingmousemodels of sterile injuries of the skin and
the liver and it is not known yet whether this is also happening in other
tissues or in all types of injury (Dal-Secco et al., 2015; Rodero et al.,
2014). The role of monocytes during wound healing is to some extent
similar to that of neutrophils since they also phagocytose tissue debris
and pathogens (similarities and differences between these cell types
havebeen reviewedelsewhere (Dale et al., 2008).However,monocytes
function in a more complex way than neutrophils, as they also give ori-
gin to other cells important for wound healing, such as macrophages,
DCs, and fibrocytes.
During monocyte maturation in mice, two monocyte subpopula-
tions are found. Monocytes formed in bone marrow are character-
ized by high expression of Ly6C (Ly6Chi). These Ly6Chi monocytes can
migrate from bone marrow to blood after stimulation with CCL2 and
CCL7, which is why they have high expression of the chemokine recep-
tor CCR2 (Auffray et al., 2009; Tsou et al., 2007). Ly6Chi monocytes,
also known as classical monocytes, have a pro-inflammatory pheno-
type and thus are the ones usually found during acute injury. Classical
monocytes can develop into nonclassicalmonocytes,which are charac-
terized as Ly6Clow and CX3CR1-positive with a prohealing phenotype
(Hanna et al., 2015; Hettinger et al., 2013; Yona et al., 2013). In steady
state conditions classical monocytes are found patrolling extravascu-
lar tissues while nonclassical monocytes are found patrolling blood
vessels (Auffray et al., 2007; Carlin et al., 2013). This patrolling behav-
ior, at least in the case of the nonclassical monocytes, was shown to
provide immune surveillance to the surrounding tissues since they
were shown to extravasate rapidly into a tissue that has been submit-
ted to sterile, toxic, or infectious injury (Auffray et al., 2007). Interest-
ingly, these nonclassical patrolling monocytes were found enriched in
the lung microvasculature and were shown to have a protective effect
against cancer by reducing tumor metastasis through the recruitment
of other immune cells (Hanna et al., 2015).
In humans, monocytes possess a different molecular nomen-
clature but it seems from the limited studies available in humans
that they behave similarly to those in mice. Human monocytes are
classified based on their expression of CD14 (a membrane receptor
for lipopolysaccharide [LPS]) and CD16 (a low affinity immunoglob-
ulin G receptor). With these two markers it is possible to identify
three monocyte populations in human blood: CD14++CD16− (clas-
sical monocytes), CD14+CD16+ (intermediate monocytes), and
CD14+CD16++ (nonclassical monocytes), accounting for around
85%, 5% and 9% of all monocytes, respectively (Glezeva, Horgan,
& Baugh, 2015; Hulsmans, Sam, & Nahrendorf, 2016; Shi & Pamer,
2011; Wang & Xia, 2013; Woollard & Geissmann, 2010; Ziegler-
Heitbrock & Hofer, 2013). Additionally, just as in mice the human
classical subtype is CCR2+ and the nonclassical subtype is CX3CR1+
(Tacke & Randolph, 2006). Similar to what occurs in mice, human
nonclassical CD14+CD16− monocytes are thought to originate from
classical CD14++CD16−monocytes in blood in anM-CSF-dependent
way (Korkosz, Bukowska-strakova, Sadis, Grodzicki, & Siedlar, 2012;
Weiner et al., 1994; West et al., 2012). This differentiation happens
via the formation of the intermediate phenotype, which has been
associated with different pathological conditions such as cardiovas-
cular disease, trauma, sepsis, and autoimmunity (Rossol, Kraus, Pierer,
Baerwald, & Wagner, 2012; Tapp, Shantsila, Wrigley, Pamukcu, & Lip,
2012; Urra et al., 2009; West et al., 2012). It is hypothesized that
increased numbers of intermediate monocytes in these diseases are
triggered by tissue damage and could be functionally associated with
tissue repair and regeneration (Schauer et al., 2014).
Monocytes are well known for being possible progenitors of
macrophages and DCs. Due to their ability to change into these cells,
monocytes can also indirectly contribute to disease. However, there
is evidence that they can influence wound-healing processes while
maintaining their monocytic phenotype (Dal-Secco et al., 2015).
Jakubzick et al. (2013) showed that monocytes are able to move
through tissues and migrate towards lymph nodes maintaining their
monocytic phenotype without differentiating to DCs or macrophages.
Mouse studies suggest that monocytes infiltrate the injured tissue
in two waves: the first wave involves an influx of classical Ly6Chi
CCR2+ monocytes contributing to inflammation and angiogenesis
followed by a later influx of nonclassical Ly6Clow CX3CR1+monocytes
that contribute to scar formation (Ishida, Gao, & Murphy, 2008;
Willenborg et al., 2012). In the context of liver injury in particular it
was shown by Dal-Secco and colleagues that monocytes themselves
can restore homeostasis after tissue injury without differentiating
into macrophages (Dal-Secco et al., 2015). These authors showed
via intravital microscopy that classical Ly6Chi CCR2+ monocytes
8 FLOREZ-SAMPEDRO ET AL.
that infiltrated mouse liver tissue after a sterile injury changed their
phenotype in situ towards nonclassical Ly6Clow CX3CR1+monocytes.
This change was IL-4 and IL-10 dependent and associated with a
decrease in dead cells and tissue debris. This suggests that monocytes
are capable of re-establishing homeostasis of tissues without relying
on differentiation to macrophages or the recruitment of other cells.
Furthermore, this could mean that what initially was conceived as a
process involving two waves of infiltration might actually be a trans-
formation of inflammatory classical monocytes towards a nonclassical
prohealing phenotype. It is possible, however, that the resolution
of injury observed in this study also had a contribution from local
macrophages. It is not known whether this classical-to-nonclassical
monocyte differentiation in situ occurs in the lung and other tissues
and with other types of injury. These observations challenge the
idea of some researchers to refer to infiltrating tissue monocytes as
macrophages and reflect the possible influence of monocytes on the
fate of a tissue after injury. To be noted, although these observations
originate from mouse studies, it is likely that this in situ monocyte
conversion also occurs in humans due to the similarities in the classical
and nonclassical subtypes of monocytes in mouse and humans.
In the context of fibrosis there is someevidence that classical Ly6Chi
monocytes promote the fibrotic process. In a mouse model of pul-
monary fibrosis, thedepletionof classical Ly6Chi monocytes resulted in
less fibrosis, and additionally the adoptive transfer of thesemonocytes
aggravated fibrosis (Gibbons et al., 2011). Although depletion of clas-
sical Ly6Chi monocytes led to a decrease in the numbers of profibrotic
macrophages (Ym1-positive alternatively activatedmacrophages), this
study was not able to prove that these macrophages originate from
classical Ly6Chi monocytes. Another study using two mouse mod-
els of liver fibrosis showed that inhibiting the accumulation of classi-
cal Ly6Chi monocytes during the resolution phase of fibrosis acceler-
ated scar resolution (Baeck et al., 2014). This shows that also in liver
fibrosis the classical Ly6Chi monocytes contribute to the fibrotic pro-
cess. Gibbons and colleagues hypothesized that classical Ly6Chi mono-
cytes could contribute to the fibrotic process by means of cell-to-cell
interactions with macrophages and possibly even myofibroblasts in
the fibrotic foci of the developing fibrotic lung. This is supported by
Mewhort and colleagues, who showed that human monocytes from
peripheral blood (which were 95% classical monocytes) induce the
activation of cardiac fibroblasts towardsmyofibroblasts via direct cell-
to-cell interaction, to a greater extent than the effect of TGF-𝛽 on
fibroblasts (Mewhort et al., 2016).
Most studies on immune responses in fibrosis have focused on the
influence of monocyte-derived macrophages and not on monocytes
per se, and it is therefore still unclear what the actual contributions
of the classical Ly6Chi and nonclassical Ly6Clo monocytes are to the
fibrotic process. Considering that monocytes are one of the first cell
types to arrive at injured tissue, and based on the different abilities
they have, they play an important role in defining whether an initial
insult is suitably repaired or develops into a chronic condition. It is pos-
sible that Ly6Chi profibrotic monocytes are the origin of profibrotic
macrophages. Perhaps modern techniques like intravital microscopy
and the use of fluorescent monocytes (labeled or genetically fluores-
cent) can clarify this.
3.1.2 Macrophages
Macrophages are tissue-resident myeloid leukocytes belonging to the
innate immune system that are key in maintaining tissue homeosta-
sis. They have heterogeneous functions ranging from phagocytosis of
microorganisms, ECM components, or dying cells to the production
of cytokines for the modulation of other cells involved in immune
responses (Murray &Wynn, 2011). Overall, they are capable of main-
taining tissue homeostasis by developing into different phenotypic
populations according to what the tissue environment requires at
that moment. Mouse studies depleting macrophages during different
stages after tissue injury have shown that macrophages are impor-
tant for the inflammatory, the prohealing, as well as the resolution
stages of wound healing (Duffield et al., 2005; Gibbons et al., 2011).
Studies with salamanders have shown that their great regenerative
capacity is actually dependent on macrophages (Godwin, Pinto, &
Rosenthal, 2013). Godwin and colleagues showed in adult salaman-
ders that the regeneration of whole limbs after amputation was ham-
pered upon macrophage depletion, thus reflecting the importance of
macrophages in tissue repair.
Depending on their phenotype and role, macrophages can be
broadly classified as M1 and M2, although in reality there is a
spectrum of phenotypes (Gautier et al., 2012; Hume, 2015). M1
macrophages, also known as classically activated macrophages, are
pro-inflammatory, associate with Th1 inflammation, and are activated
immediately after tissue injury or infection. M2macrophages, or alter-
natively activatedmacrophages, associate with Th2 inflammation, res-
olution of inflammation, and tissue repair (Martinez & Gordon, 2014;
Mills, 2015).M2macrophages canbe generatedbymany stimuli, which
is why this type is often subdivided into three classes: M2a, acti-
vated by IL-4 or IL-13; M2b, activated by immune complexes; M2c,
activated by IL-10, TGF-𝛽 and glucocorticosteroids (Martinez & Gor-
don, 2014; Martinez, Sica, Mantovani, & Locati, 2008; Murray et al.,
2014). In healthy conditions, M1 macrophages would be involved in
the first stages of wound healing, due to their pro-inflammatory phe-
notype, and M2 macrophages would follow leading to a decrease in
inflammation and the beginning of a repair process that eventually
will re-establish homeostasis and tissue structure (Adhyatmika et al.,
2015; Braga, Agudelo, & Camara, 2015). Additionally, there are some
indications that M1 macrophages may also be important during res-
olution of fibrosis. Our studies on the liver in the context of liver
fibrosis have shown that M1-polarized macrophages persist during
resolution of liver fibrosis, while the number of M2 macrophages
decreases (Beljaars et al., 2014). In addition, forcing liver macrophages
to polarize towards M2 by macrophage-specific delivery of corticos-
teroids aggravates the fibrotic process in the liver (Melgert et al.,
2001). Gibbons et al. (2011) and He, Ryan, Murthy, and Carter (2013)
have shown similar findings for the lung.
Macrophages can originate from blood monocytes during inflam-
mation after monocytes have infiltrated the injured tissue (Murray
& Wynn, 2011). However, not all tissue macrophages originate from
monocytes. It is now known that many tissue-resident macrophages,
including alveolar macrophages, originate from yolk sac macrophages
or from erythro-myeloid progenitors in the fetal liver (Ginhoux &
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Guilliams, 2016; Ginhoux et al., 2010; Guilliams et al., 2013; Hoef-
fel et al., 2012, 2015; McGrath et al., 2015; Schulz et al., 2012).
These tissue-resident macrophages in steady state conditions are self-
renewing and long-lived, but under inflammatory conditions they can
be supplementedby infiltratingmonocytes (Epelmanet al., 2014;Heidt
et al., 2014; Hilgendorf et al., 2014;Movita et al., 2015). It is important
tomake a distinction between these two types ofmacrophages, as they
may function in different and even opposite ways in some conditions
(Gundra et al., 2014; Vannella et al., 2014; Zaslona et al., 2014).
In pathological conditions or after repeated tissue insults the bal-
ance, interactions, and roles of the different macrophage subsets may
be altered. Overall, it is known that many lung diseases present with
altered numbers and functions of macrophages (reviewed by Boorsma
et al., 2013). The particular case of pulmonary fibrosis is thought to
associate with higher numbers of M2 macrophages, reflected by the
high expression of M2 markers in IPF lavage fluid and in mouse mod-
els for pulmonary fibrosis (Boorsma et al., 2013; Gibbons et al., 2011;
Pechkovsky et al., 2010), suggesting an attempt to repair the tissue.
This is not surprising as M2 macrophages associate with repair pro-
cesses and may directly stimulate myofibroblasts via TGF-𝛽 to pro-
duce and deposit the ECM that characterizes the fibrotic process
(Conway & Hughes, 2012). An uncontrolled increase in this activity
could turn a “prohealing” activity into a “profibrotic” effect. This notion
is also supported by the study from Gibbons and colleagues, in which
they demonstrate that alternatively activated M2 macrophages are
directly involved in the development of pulmonary fibrosis (Gibbons
et al., 2011). Considering these data, it is understandable why gluco-
corticosteroid treatment can worsen pulmonary fibrosis, as this treat-
ment activates a class of M2 macrophages. However, it is unknown
whether the origin of these profibrotic macrophages in pulmonary
fibrosis is from resident alveolar or interstitial macrophages or from
infiltrating monocytes. It has been suggested that, in liver fibrosis,
both resident liver macrophages (Kupffer cells) andmonocyte-derived
macrophages contribute to the development of fibrosis (Baeck et al.,
2014; Pradere et al., 2013). It still needs to be elucidated whether it
is the same for pulmonary fibrosis. Interestingly, it has been shown in
a mouse model of asthma that alveolar macrophages control inflam-
mation, while monocyte-derived macrophages promote inflammation
after exposure to house dust mite (Zaslona et al., 2014). Although this
is not reflecting what occurs in pulmonary fibrosis, it suggests that
upon exposure to inflammatory triggers lung-resident macrophages
may play an opposite role to that of monocyte-derived macrophages
and this may also be relevant for pulmonary fibrosis.
To conclude, macrophages are multifaceted leukocytes that are key
for wound healing. They can present differentially polarized pheno-
types based on the triggers they are exposed to and the microenvi-
ronment of the niche they belong to. They are involved in the inflam-
matory, the healing, and the resolution phase of tissue repair, and they
can exist as resident tissuemacrophages originating during embryonic
development or they could develop from infiltrating monocytes. Their
different origins influence their behavior and possibly their involve-
ment in pathological conditions. However, the exact contribution of
each of these macrophages (i.e., tissue-resident vs. recruited) in fibro-
sis, particularly in the lung, still needs to be clarified.
3.1.3 Dendritic cells
DCsmature frommyeloid progenitor cells after stimulation with gran-
ulocyte macrophage colony stimulating factor (GM-CSF), IL-4, tumor
necrosis factor alpha (TNF-𝛼), and FMS-like tyrosine kinase 3 ligand
(FLT3L) (Ardavín, 2003; Ardavín et al., 2001). DCs are distributed
through most lymphoid and nonlymphoid tissues, acting as sentinels,
and are also present in peripheral blood, constituting 0.1−1% of all
mononuclear cells (Orsini et al., 2012). Generally, lung resident DCs
can be divided into two major classes: plasmacytoid DCs (pDCs) and
conventional or classical DCs (cDCs). Under inflammatory conditions,
monocyte-derived DCs (moDCs) can also be found in the lung as well
(Ganguly, Haak, Sisirak, & Reizis, 2013; Kim& Lee, 2014).
cDCs originate from hematopoietic stem cells in bone marrow that
develop into lineage-restricted macrophage-DC progenitors, which in
turn differentiate into common DC progenitors (Naik et al., 2007;
Sathe et al., 2014). These common DC progenitors give rise to pre-
DCs that migrate into peripheral tissues and locally differentiate into
mature cDCs mainly dependent on FLT3L (Kopf, Schneider, & Nobs,
2015). cDCs are dedicated antigen-presenting cells with a high expres-
sion of major histocompatibility complex class II (MHCII).
pDCs also originate from hematopoietic stem cells but, in con-
trast to cDCs, pDC development occurs completely in bone marrow
and mature pDCs migrate to peripheral tissues (Reizis, Bunin, Ghosh,
Lewis, & Sisirak, 2011). M-CSF and IL-7 contribute to pDC develop-
ment together with FLT3L (Waskow et al., 2008). pDCs express rela-
tively low levels of MHCII and rapidly produce type I interferons (IFN)
following activation through nucleic acid sensing TLRs (Ardavín, 2003;
Ganguly et al., 2013).
During inflammation, classical Ly6Chi and nonclassical Ly6Clo
monocytes can serve as precursors formoDCs and are recruited to the
lung by pro-inflammatory chemokines such as CCL2 and CCL7 and the
cytokineCSF-1 (Hoffmannet al., 2016).However, it is difficult todistin-
guish between moDCs and cDCs due to their similar surface markers.
Overall, DCs are the primary professional antigen presenting cells and
they connect the innate andadaptive immune systemvia uptake, trans-
port, processing, and presentation of antigens to T cells, and cytokine
production (Guilliams, Lambrecht, & Hammad, 2013).
DCs can take up and remove foreign particles and pathogens in
a similar way to macrophages, which is partly why they also play an
important role in wound healing. Resident DCs can also get activated
via TLRs after sensing local danger signals produced by injury (Hartl
et al., 2012). Additionally, pDCs can secrete type I IFNs to promote
wound healing (Gregorio et al., 2010). The overall importance of DCs
in wound healing is demonstrated in DC-deficient mice that present
with a significant delay in early wound healing after contact burns
(Gregorio et al., 2010). Moreover, compared to control mice, DC-
deficient mice had lower levels of TGF-𝛽 . This suggests that DCs
secrete factors such as TGF-𝛽 that are important for other cells during
wound healing. Interestingly, another study using DC-depletedmice in
a model of myocardial infarction showed that, in the absence of DCs,
the ratio ofM1:M2macrophages in the infarcted area was higher than
that of control mice (Anzai et al., 2012). This means that DCs normally
promote a repair phenotype inmacrophages after tissue damage.
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Due to their role in tissue repair, it is not surprising thatDCs are also
associated with pulmonary fibrosis. It was reported that large num-
bers of cDCs accumulatewithin fibroblast foci in lungs of patients with
pulmonary fibrosis (Marchal-Sommé et al., 2007). A mouse model of
bleomycin-induced pulmonary fibrosis showed that during the inflam-
matory phase monocytes recruited into the lung rapidly differenti-
ated into DCs. Subsequently, higher numbers of mature DCs express-
ing MHCII, CD40, CD83, and CD86 surface molecules were found
in lung tissue during the repair phase compared to the inflamma-
tory phase (Bantsimba-Malanda et al., 2010). This suggests that DCs,
just as described before, are important in the repair phase possibly
because of their effect on other immune cells. Moreover, DCs are
also thought to play a role in fibrosis through communication with
fibroblasts. Recently, DCs and fibroblasts were found to co-localize
within the renal interstitium in human kidney, suggesting the possibil-
ity of direct crosstalk between the two cell types (Dixon, Rossmann,
Kamerling, & van Kooten, 2014). In addition, lung fibroblasts were
shown to have a crucial role in regulating both fibrotic and immune
responses by secreting chemokines that direct DC trafficking from
the lung to themediastinal lymph node through TGF-𝛽 𝛼v𝛽8-mediated
activation (Kitamura et al., 2011). Freynet and colleagues demon-
strated that co-culture of human lung fibroblasts (from both con-
trol and IPF lung tissue) with immature DCs resulted in lower
expressions of MHCII, CD86, and CD83 on DCs with a concomi-
tant decrease in their T cell stimulatory activity (Freynet et al.,
2016). This suggests that lung fibroblasts act as immunoregu-
latory cells able to modulate the maturation of DCs by main-
taining them in an immature state within fibrotic lesions, which
could inhibit T cell proliferation. This is of importance as several
studies have shown that DCs play a critical role in bleomycin-
induced pulmonary fibrosis by regulating T cell activation (Bayes,
Bicknell, MacGregor, & Evans, 2014; Pociask et al., 2011; Trujillo,
Hartigan, & Hogaboam, 2010). DCs in bleomycin-exposed lung tis-
sue express high levels of CD86, which can result in activation of T
cells through CD28. In fact, studies with CD28-deficient mice indi-
cate that T cell co-stimulation via CD28 is crucial for the development
of bleomycin-induced pulmonary fibrosis (Okazaki et al., 2001). These
studies suggest that mature DCs play a role in pulmonary fibrosis by
providing co-stimulatory signals (CD28−CD86) for T cell activation.
In conclusion, DCs are important during tissue repair and play a
potential role in pulmonary fibrosis. However, how DCs contribute to
fibrogenesis is still poorly understood. The evidence thus far supports
the idea that DCsmay contribute to a repair response in fibrosis by the
interaction and subsequent influence on fibroblasts,macrophages, and
T cells. These interactions still require further investigation.
3.1.4 Fibrocytes
Fibrocytes are circulating bone-marrow-derived myeloid cell progen-
itors that can differentiate into fibroblasts and myofibroblasts once
they enter tissues. Upon tissue damage, fibroblasts concentrate in
the area of injury under the influence of chemokines and cytokines
produced by the injured tissue. They contribute to rebuilding tissue
by producing high quantities of ECM components (Gabbiani, 2003;
Midwood, Williams, & Schwarzbauer, 2004). This process intensifies
after they transform into contractile myofibroblasts expressing alpha
smoothmuscle actin and secreting evenmoreECMcomponents,which
allows for wound contraction. However, myofibroblasts are also the
most important cells responsible for the excess production of ECM in
fibrotic processes and, at least in the case of pulmonary fibrosis, they
can originate from monocyte-derived fibrocytes (Andersson-Sjöland
et al., 2008; Kendall & Feghali-Bostwick, 2014).
In 1994, fibrocytes were first described as circulating monocyte-
derived cells that migrate into sites of tissue injury and express a
fibroblast-like phenotype in scar-tissue-like lesions such as cardiovas-
cular disease, pulmonary fibrosis, and even normal ageing (Bucala,
Spiegel, Chesney, Hogan, & Cerami, 1994). Circulating fibrocytes
comprise approximately 0.1−0.5% of leukocytes in peripheral blood
and they rapidly enter tissues and contribute to tissue remodeling
after injury (Dupin et al., 2016; Herzog & Bucala, 2010). To mediate
their entry into inflamed tissues after damage, fibrocytes express the
chemokine receptors CCR2, CCR7, and CXCR4 (Dupin et al., 2016;
Ekert et al., 2011; Fu et al., 2015).
Fibrocytes are a unique population of immune cells because they
possess characteristics both of hematopoietic cells and of mesenchy-
mal cells (Reese et al., 2014; Suga et al., 2014). They express the
hematopoietic cell markers CD34, CD45, Fc𝛾R, LSP-1, andMHCII, but
they also express stromal cell markers such as collagens, fibronectin,
andMMPs (Peng&Herzog, 2012). It is currently accepted that themin-
imum number of markers necessary for identifying fibrocytes in cul-
ture, in tissue sections, or in the circulation are the expressions of colla-
gen I and CD45 (Fujiwara et al., 2012). However, due to their apparent
plasticity and the lack of consensus on other cellular features, such as
granularity, there is still a need for an accurate gating approach for the
further characterization of functional aspects of fibrocytes.
Previous studies reported that patients with pulmonary fibrosis
have higher percentages of circulating fibrocytes than healthy individ-
uals (6−10% vs. 0.5%) (Mehrad et al., 2007). This has been reported
in other fibrotic diseases as well, and therefore it appears that there
is a pivotal link between fibrocytes and wound healing and fibrosis
(Grieb & Bucala, 2012; Kendall & Feghali-Bostwick, 2014). There are
several possible explanations of how these high percentages of fibro-
cytes could play a role in wound healing and fibrotic processes.
First, fibrocytes themselves could produce essential ECM proteins
that are involved in wound repair and fibrosis. Reports show that
fibrocytes are a source of lung fibroblasts in IPF and can differenti-
ate into myofibroblasts once they enter into lung tissue (Andersson-
Sjöland et al., 2008). Fibrocytes were shown to express numerous
ECM molecules, including vimentin, fibronectin, and collagens (Fan,
Takawale, Lee, & Kassiri, 2012). Nonetheless, in comparison to fibrob-
lasts, human fibrocytes have a matrix-stabilizing function, as opposed
to the predominant matrix-building function of tissue fibroblasts
(Bianchetti et al., 2012). Second, fibrocytes could drive proliferation,
migration, and ECM production by resident fibroblasts. Prior studies
proposed that collagen I produced by fibrocytes could promote fibrob-
last activation (Chesney, Metz, Stavitsky, Bacher, & Bucala, 1998).
Fibrocytes may also influence resident epithelial or mesenchymal cells
to differentiate into myofibroblasts by the production of important
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profibrotic cytokines (e.g., TNF-𝛼, IL-6, IL-10), chemokines (e.g., CCL3,
CCL4, CCL2, CXCL8, and growth-related oncogene-alpha) and growth
factors (e.g., M-CSF, TGF-𝛽 , platelet-derived growth factor [PDGF],
insulin-like growth factor-1, angiogenin) (Andersson-Sjöland et al.,
2008; Bellini & Mattoli, 2007; Grieb & Bucala, 2012; Schmidt, Sun,
Stacey,Mori, &Mattoli, 2003). Third, a positive feedback loop between
fibroblasts and fibrocytes may enhance fibrosis. Pilling and colleagues
showed that fibroblasts stimulated with fibrocyte-secreted TNF-𝛼 can
secrete lumican, which in turn acts directly on monocytes to differen-
tiate into fibrocytes (Pilling, Vakil, Cox, & Gomer, 2015). In addition,
the level of lumicanwasmuch higher in both human pulmonary fibrotic
lesions and in amousemodel of bleomycin-induced pulmonary fibrosis
(Pilling et al., 2015). These resultsmayexplainwhy fibrocytes are rarely
identified in healthy lung, heart, and liver tissue, but are easily detected
in fibrotic lesions. Lastly, fibrocytes could be involved in the stimula-
tion of angiogenesis via the production of MMP9, vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF), CXCL8,
and PDGF (Garcia-de-Alba et al., 2010; Hartlapp et al., 2001; Smadja
et al., 2014).
Pulmonary fibrosis has a high mortality rate with few effective
drugs and even fewer reliable biomarkers for clinical management of
patients. In 2009, several studies demonstrated that circulating fibro-
cytes could be a potential biomarker in pulmonary fibrosis predicting
the progression of the disease (Lapar et al., 2011; Moeller et al., 2009;
Strieter, Keeley, Burdick, & Mehrad, 2009). They found that the sur-
vival rate of patients with pulmonary fibrosis withmore than 5% fibro-
cytes of total blood leukocyteswas around 7months, whereas patients
with less than 5% fibrocytes lived for an average of 27 months after
establishing fibrocyte percentages. Of the drugs against pulmonary
fibrosis currently on themarket, both pirfenidone and nintedanibwere
shown to affect fibrocytes which could thus be an explanation for
their beneficial effects in patientswith pulmonary fibrosis (Axell-house
et al., 2017). Pirfenidone was shown to diminish the fibrocyte pool and
the migration of these cells in bleomycin-induced pulmonary fibrosis
in mice (Inomata et al., 2014), and for nintedanib it was found that
it inhibits the migration and differentiation of fibrocytes induced by
growth factors in vitro (Sato et al., 2017). The number of fibrocytes in
the bleomycin-induced pulmonary fibrosis model was reduced by the
administration of nintedanib and this was associated with antifibrotic
effects (Sato et al., 2017).
An inhibitor of monocyte-to-fibrocyte differentiation, known as
PRM-151 (recombinant human serum amyloid pentraxin 2), is cur-
rently being developed and tested as a potential treatment for pul-
monary fibrosis (Dillingh et al., 2013). Pentraxin 2 was also found to
promote differentiation of monocytes into regulatory macrophages,
and preclinical studies using recombinant pentraxin 2 in mice and rats
have shown a reduction in bleomycin-induced pulmonary fibrosis. The
first clinical applications have shown that PRM-151 has antifibrotic
effects and is well tolerated with a favorable pharmacokinetic profile
without serious adverse reactions (VanDen Blink et al., 2016).
In summary, fibrocytes are connected to fibrotic processes through
their differentiation into myofibroblasts, their promotion of local
(myo)fibroblast differentiation, and their regulation of other processes
like angiogenesis. However, the lack of a standard technique for the
accurate characterization of fibrocytes hampers the identification of
their biological functions in pathological conditions. More studies are
necessary to determine the exact functional and phenotypical over-
lap between the myofibroblasts originating from fibrocytes and from
fibroblasts and the contribution of each type to fibrotic diseases.
3.2 Granulocytes
3.2.1 Neutrophils
Neutrophils are polymorphonuclear leukocytes that originate from
bone marrow myeloid progenitors under the influence of granulo-
cyte colony stimulating factor (G-CSF) (Lieschke et al., 1994). They
are considered as short-lived cells with a lifespan of about 12.5 h in
mice and 5.4 days in humans, although their longevity increases up
to sevenfold once they are activated (Pillay et al., 2010; Summers
et al., 2010). In steady state, neutrophils can be found in bone mar-
row, spleen, liver, and lung (Peters, 1998; Summers et al., 2010). The
reason why neutrophils concentrate in these tissues is not completely
understood and it has been suggested that these organs could function
as a reservoir of mature neutrophils (Kolaczkowska & Kubes, 2013).
Interestingly, the lung seems to contain a particularly great number
of mature neutrophils (Sibille & Marchandise, 1993). Based on lung
intravital microscopy studies, these neutrophils appear to be crawling
and patrolling the lung vasculature, although the exact purpose of this
behavior remains to be elucidated (Kreisel et al., 2010).
Neutrophils are typically the first cells to arrive at an injured tissue.
This is to be expected as neutrophils are themost abundant leukocytes
in human blood and they normally function as a containing barrier
for potential infectious threats (Kolaczkowska & Kubes, 2013; Yang,
Feng, Zhang, Lu, & Zhao, 2016). The antimicrobial functions of neu-
trophils consist of phagocytosis of microbes, exocytosis of enzymes
and antimicrobial compounds, production of reactive oxygen species,
and the release of neutrophil extracellular traps (NETs) (Brinkmann
et al., 2004; Segal, 2005).
In addition to their antimicrobial function, neutrophils can phago-
cytose tissue debris produced by injury and they can promote the
healing process by recruiting more neutrophils and other leukocytes
through the production of mediators such as IL-17, leukotriene B4,
VEGF-A, and chemokines (Kolaczkowska & Kubes, 2013; Wilgus, Roy,
& McDaniel, 2013; Zemans et al., 2011). It was initially believed that
neutrophils, shortly after fulfilling their function in injured tissue,
would die by apoptosis and would be phagocytosed by macrophages
(Buckley, Gilroy, Serhan, Stockinger, & Tak, 2012). However, Hughes
and colleagues showed that neutrophils do not always die by apopto-
sis and have an alternative fate known as “reversed migration.” This
process involves the migration of neutrophils away from the injured
area and ultimately re-entering the vasculature (Hughes et al., 1997).
It is still unclear whether this behavior is associated with a change
in the activation status of neutrophils that could lead to a spread of
the inflammation. Uncontrolled activation of neutrophils can hamper
the healing process, which could lead to pathological conditions. It has
been shown that altered numbers and increased activity of neutrophils
can contribute to the pathogenesis of lung diseases such as asthma and
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COPD (Deckers,Madeira,&Hammad, 2013;Grabcanovic-Musija et al.,
2015; Haldar & Pavord, 2007; Holgate, 2012; Pedersen et al., 2015;
Qiu et al., 2003;Wright et al., 2016).
Neutrophils were also shown to be important in the context of pul-
monary fibrosis. In IPF, highpercentagesof neutrophils inbronchoalve-
olar lavage fluid of patients correlated to early mortality (Kinder et al.,
2008). In addition to high neutrophil counts, neutrophil activity was
found to be altered in pulmonary fibrosis; biopsies from patients with
pulmonary fibrosis show NET expression close to myofibroblasts and
neutrophil elastase levels are higher in lavage fluid and plasma of IPF
patients compared to nonsmoker controls (Chrysanthopoulou et al.,
2014; Obayashi et al., 1997). Interestingly, despite the ECM degrad-
ing ability of neutrophil elastase it also appears to be contributing
to the pathogenesis of pulmonary fibrosis. A study with neutrophil-
elastase-deficient mice showed that its absence was associated with
an attenuation of the characteristics of pulmonary fibrosis (Chua et al.,
2007). This is supported by another murine study that demonstrated
that neutrophil-elastase-deficient mice present a significant reduction
in fibroblast and myofibroblast accumulation in comparison to wild
type mice and that elastase deficiency protected mice from asbestos-
induced pulmonary fibrosis (Gregory et al., 2015). Moreover, a mouse
model of pulmonary fibrosis induced by chronic fungal infection with
Paracoccidioides brasiliensis showed that depletion of neutrophils could
attenuate pulmonary fibrosis and inflammation (Puerta-Arias, Pino-
Tamayo, Arango, &Gonzalez, 2016). This suggests that, at least in these
models, the pro-inflammatory activity of neutrophils, possibly through
the production of neutrophil elastase and other compounds, can pro-
mote tissue injury leading to a continuous activation of myofibroblasts
in an attempt to heal the tissue, therefore promoting fibrosis.
It is clear from these and other recent studies that neutrophils may
have a bigger impact on wound healing and fibrosis development than
just being the first responders to tissue injury, as they may play roles
beyond phagocytosis and immune cell recruitment (Yang et al., 2016).
Neutrophil apoptosis alonemay skew the polarization ofmacrophages
towards an M2 phenotype with increased IL-10 and decreased IL-
12 and IL-23 production, thus promoting tissue repair (Filardy et al.,
2010).Moreover, in the past years studies have shown that neutrophils
themselves can polarize to N1/N2 profiles (pro-inflammatory/anti-
inflammatory), similar to the polarization observed in macrophages
(Fridlender et al., 2009). So far, these neutrophil phenotypes have
mostly been studied in the context of tumors and their roles and impli-
cations in fibrosis are, to our knowledge, still unknown. These inter-
esting discoveries show that neutrophils may be more important than
usually considered and therefore itmight beof interest for future stud-
ies to focus on the role of this cell type in the pathogenesis of fibrotic
diseases.
3.2.2 Eosinophils
Eosinophils are part of the granulocyte family and account for 1−3%
of all leukocytes (Eltboli & Brightling, 2013). They originate from the
commonmyeloid progenitor in bone marrow via stimulation with IL-3,
IL-5, and GM-CSF (Denburg, 1999; Wardlaw, Brightling, Green,
Woltmann, & Pavord, 2000). This stimulation leads to their
maturation to eosinophils and their migration to blood. In blood,
mature eosinophils have a short lifespan of about 8−18 h, but it can
be extended to 2−14 days depending on the tissues they reach and
the cytokines present in that niche (Park & Bochner, 2010). Once in
blood they can be recruited to the lung under the influence of CC
chemokines (also known as eotaxins), such as CCL11 (Uhm, Kim, &
Chung, 2012). In lung tissue, the function of eosinophils is thought to
be regulated by Th2 cells via the production of IL-4, IL-5, and IL-13,
which makes eosinophils bind strongly to airway vessels and survive
apoptosis (Saha & Brightling, 2006; Symon et al., 1996; Wardlaw,
1999;Woltmann,McNulty, Dewson, Symon, &Wardlaw, 2000).
Eosinophils have mostly been associated with immune responses
against helminths and other pathological organisms and with
Th2-related inflammatory responses (Acharya & Ackerman, 2014;
Uhm et al., 2012). They exert their functions through production of
granules containing major basic protein, eosinophil cationic protein,
eosinophil peroxidase, and eosinophil-derived neurotoxin (Acharya &
Ackerman, 2014). Although these compounds aim to kill pathogens,
they are also toxic to host cells, which is probably why they contribute
to airway inflammation. High numbers of eosinophils and high levels of
proteins from their granules have been associated with lung diseases
such as asthma and COPD (Eltboli & Brightling, 2013).
In the case of pulmonary fibrosis, a series of studies in the last three
decades have connected eosinophils to pulmonary fibrosis by evaluat-
ing the cellular composition of lavage fluid and sputum of pulmonary
fibrosis patients and control individuals. These reports show that
eosinophil counts and activity (i.e., levels of eosinophil cationic pro-
tein) are higher in pulmonary fibrosis patients in comparison to control
individuals (Birring et al., 2005; Fujimoto, Kubo, Yamaguchi, Honda,
& Matsuzawa, 1995; Hällgren, Bjermer, Lundgren, & Venge, 1989;
Peterson, Monick, & Hunninghake, 1987; Rudd, Haslam, & Turner-
Warwick, 1981;Watters et al., 1987). The high numbers of eosinophils
in pulmonary fibrosis lungs are thought to be associated with the
expression of TNF-𝛼 and possibly also with the release of eosinophil
chemotactic activity by lung fibroblasts and bronchial epithelial cells
(Sato, Koyama, & Robbins, 2000; Zhang, Gharaee-Kermani, McGarry,
Remick, & Phan, 1997). Zhang and colleagues showed that, in a mouse
model of bleomycin-induced fibrosis, neutralizing TNF-𝛼 resulted in
lower eosinophil numbers and less development of pulmonary fibrosis
(i.e., lower hydroxyproline content). However, it could be argued that
this study provides evidence of the importance of TNF-𝛼 in the inflam-
matory responses that precede fibrosis in the bleomycin model rather
than evidence for the role of eosinophils in fibrosis. This is supported
by the work of Hao and colleagues in which they show that fibrosis
development is independent of eosinophilic infiltration (Hao, Cohen,
Jennings, Bryson, & Kaplan, 2000). These authors showed that genetic
deficiency or depletion of IL-5 resulted in significantly lower eosinophil
counts and activity, but development of bleomycin-induced pulmonary
fibrosis was not affected by the absence of eosinophils. This sug-
gests that even if eosinophils migrate to the lung before the establish-
ment of fibrosis, they do not seem to contribute to the actual fibrotic
process.
The strongest evidence connecting eosinophils to pulmonary fibro-
sis is the fact that they are present in lavage fluid and sputum of
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pulmonary fibrosis patients (Birring et al., 2005; Fujimoto et al., 1995;
Hällgren et al., 1989; Peterson et al., 1987; Rudd et al., 1981; Watters
et al., 1987). This does not necessarily mean that they contribute sig-
nificantly to fibrosis development. It is possible that they have a small
contribution, as they are known for producing TGF-𝛽 and stimulating
fibroblast proliferation in vitro (Levi-Schaffer et al., 1999). It is also pos-
sible that the cytokines produced during the inflammatory or repair
phase lead to eosinophil recruitment as a bystander effect and that the
correlation observed between eosinophil numbers and lung dysfunc-
tion in pulmonary fibrosis is just reflecting the chronic state of immune
dysregulation in the lungs of these patients and is not a causal relation.
To summarize, eosinophils are clearly involved in some types of lung
inflammation, but their role in and contribution to pulmonary fibrosis
is unclear.
3.2.3 Mast cells
Mast cells originate from hematopoietic stem cells in the bone mar-
row but complete their differentiation and maturation from mast cell
progenitors in peripheral tissues (Dahlin & Hallgren, 2015). Mast cell
progenitors are currently thought to be directly derived from multi-
potential progenitors or from common myeloid progenitors in bone
marrow (Kosanovic et al., 2015). Additionally, they may originate from
the granulocyte/macrophage progenitors in spleen (Kosanovic et al.,
2015). They circulate in blood in their immature form only and are
recruited from blood to tissue mainly through CCR2, CXCR2, CC5R,
CCL2, IL-4, and IL-12p40. Subsequently, IgE, stem cell factor (SCF),
IL-3, IL-4, IL-6, IL-9, and IL-33 are involved in the differentiation and
maturation of mast cells in tissues (Dahlin & Hallgren, 2015; Okayama
&Kawakami, 2006).
Mast cells possess intracellular granules containing histamine, hep-
arin, cytokines, proteoglycans, and proteases like tryptase and chy-
mase among others (Overed-Sayer, Rapley, Mustelin, & Clarke, 2014).
Based on whether they express tryptase and/or chymase, they can be
subdivided into two major subsets of mature mast cells in both human
and rodents: mast cells containing only chymase and mast cells con-
taining both chymase and tryptase (Dahlin &Hallgren, 2015).
In lung tissue, mast cells expressing mainly chymase are usually
found in the lamina propria and adventitia of small airways and
in between the bronchial epithelium and are called mucosal mast
cells (Andersson, Mori, Bjermer, Lofdahl, & Erjefalt, 2010). Mast cells
expressing chymase and tryptase are found in the connective tissue
of smooth muscle and in the lamina propria of small airways and
are therefore called connective tissue mast cells (Overed-Sayer et al.,
2014). It was reported that mucosal mast cells could transform into
connective tissue mast cells when co-cultured with human airway
epithelium (Martin et al., 2012).
Mast cells express two important receptors for their activation,
namely the high affinity IgE receptor (Fc𝜀R1) and the c-kit receptor.
The former leads to mast cell activation by crosslinking of antigen-
specific IgE bound to Fc𝜀R1 receptors by antigens, while the lat-
ter results in stimulation after binding of its ligand SCF (Edwards
et al., 2005; Fireman, Kivity, Shahar, Reshef, & Mekori, 1999). In addi-
tion to releasing their granular content, activated mast cells also
secrete a variety of cytokines (e.g., IL-3, IL-4, GM-CSF, TNF-𝛼, TGF-𝛽),
chemokines (e.g., CCL2, CXCL8, and CCL5), and growth factors (e.g.,
bFGF, VEGF, and PDGF) (Fireman et al., 1999; Krystel-Whittemore,
Dileepan, &Wood, 2016). Due to the production of histamine and the
presence of the Fc𝜀R1 receptor, mast cells are key players in allergic
diseases and have been associated predominantly with asthma (Galli &
Tsai, 2013; Yip, Lau, &Wise, 2011).
Additionally, mast cells play a critical role in normal tissue repair
through enhancing acute inflammation, promoting the proliferative
phase of healing, and augmenting scar formation. After injury, acti-
vatedmast cells immediately release several pro-inflammatorymedia-
tors to recruit other immune cells, such as neutrophils, into the wound
(Hart, 2001). Mast cells can also contribute to the proliferative phase
by secreting several growth factors such as VEGF, bFGF, and PDGF
to stimulate endothelial cells (Torres et al., 2002; Zhang et al., 2011).
Furthermore, during remodeling, mast cells promote fibroblast migra-
tion, proliferation, anddifferentiation intomyofibroblasts throughpro-
duction of TGF-𝛽 , PDGF, tryptase, and histamine (Artuc, Steckelings, &
Henz, 2002).
To date many studies have suggested that mast cells are involved
in fibrotic processes (Aldenborg, Nilsson, Jarlshammar, Bjermer, &
Enerback, 1993; Chanez et al., 1993; Walls, Bennett, Godfrey, Hol-
gate, & Church, 1991). Three decades ago, it was already reported that
there are high numbers of mast cells in lung biopsies of patients with
fibrotic lung disorders (Kawanami, Ferrans, & Fulmer, 1979). More-
over, high numbers of activated mast cells were observed in close
proximity to fibroblast foci in pulmonary fibrosis lung samples and
it was therefore hypothesized that the interaction of mast cells and
fibroblasts in pulmonary fibrosis may be crucial for fibrosis devel-
opment. This interaction could be mediated by chymase as it acts
as an angiotensin II-forming enzyme that converts angiotensin I to
angiotensin II. Angiotensin II has been found to stimulate fibroblast
proliferation and therefore high chymase production could promote
fibroblast proliferation (Urata, Kinoshita, Misono, Bumpus, & Husain,
1990). Interestingly, chymase inhibition has been shown to attenu-
ate pulmonary fibrosis by decreasing TGF-𝛽 expression and diminish-
ing chymase-induced fibroblast proliferation (Kosanovic et al., 2015;
Takato et al., 2011; Tomimori et al., 2003). Furthermore,Wygrecka and
colleagues found higher levels of the mast cell activator SCF in IPF
lung and IPF primary fibroblasts compared to healthy control subjects
(Wygrecka et al., 2013). In their study, they co-cultured lung fibrob-
lasts from IPF patients withmast cells and found that SCF produced by
fibroblasts enhanced mast cell survival and proliferation. Additionally,
activated/degranulatedmast cells were shown to release high levels of
tryptase, which increased lung fibroblast proliferation in a protease-
activated receptor-2-dependent manner (Villar et al., 2015). Together,
the evidence suggests that there is a positive feedback loop between
fibroblasts andmast cells in fibrotic lung tissue, which could contribute
to the fibrotic process.
In summary, mast cells play an important role in hypersensitiv-
ity and allergic responses and they may also be important contrib-
utors to fibrotic disease. The interactions between mast cells and
fibroblasts may be the most likely way of contributing to fibrosis
development.
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3.2.4 Basophils
Basophils are the rarest type of granulocytes. They are estimated to
account for less than 1% of peripheral blood leukocytes and they also
have a short lifespanof around2days (Karasuyama&Yamanishi, 2014;
Ohnmacht & Voehringer, 2009). Their development begins with the
common myeloid progenitor in bone marrow after stimulation with
IL-3, IL-5, SCF, thymic stromal lymphopoietin, and GM-CSF (Arock,
Schneider, Boissan, Tricottet, &Dy, 2002; Siracusa et al., 2011).Mature
basophils migrate to blood fromwhich they can be recruited to tissues
by an inflammatory response (Karasuyama&Yamanishi, 2014). Little is
known aboutwhich chemokines are responsible for basophilmigration
to tissues.
Basophils are well known for producing high levels of IL-4, IL-13,
and histamine and for expressing high affinity IgE receptors, which is
why they, like mast cells, associate with hypersensitivity and allergic
responses (Geering, Stoeckle, Conus, & Simon, 2013; Karasuyama &
Yamanishi, 2014). They have also been found in injured tissues dur-
ing the repair phase, although their exact role in wound healing is
not clear (López, Cervero, Jiménez, & Sánchez, 2014). Nonetheless,
they are known for being involved in Th2 responses by producing
IL-4, which may influence the function of monocytes, macrophages,
and other immune cells (Karasuyama & Yamanishi, 2014; Min et al.,
2004; Voehringer, Shinkai, & Locksley, 2004). To be noted, studies
with basophil-deficient mice have shown that, despite their Th2 con-
tribution, basophils are not necessary to establish a Th2 response.
Ohnmacht et al. showed this in a basophil-deficient mouse model,
which showed a normal recruitment of Th2 cells and eosinophils
upon infection with the helminth Nippostrongylus brasiliensis (Ohn-
macht et al., 2010). However, in this model basophils were found to
be essential in IgE-mediated chronic allergic dermatitis and protec-
tion against a second infection with N. brasiliensis. The association
of basophils with allergic responses and immunity against parasites
has also been reported by other authors (reviewed by Karasuyama &
Yamanishi, 2014; Schwartz, Eberle, & Voehringer, 2016) and has been
observed in the lung as well, but little is known about their actual
role in wound healing (Motomura et al., 2014; Ohnmacht et al., 2010;
Wakahara et al., 2013). A study using a model of basophil-dependent
allergic skin responses showed that IL-4 produced by basophils
recruited classical Ly6Chi monocytes and induced their differentia-
tion towards M2macrophages. These macrophages were beneficial in
this model since the presence of M2 macrophages protected against
allergic skin inflammation (Egawa et al., 2013). However, higher num-
bers or activity of M2 macrophages can also contribute to fibrotic
processes and in that scenario basophils become potential promot-
ers of fibrosis (Braga et al., 2015). In addition, basophils have been
suggested to promote cardiac fibrosis (i.e., cardiac transplant rejec-
tion induced fibrosis) via IL-4 production and the activation of myofi-
broblasts (Schiechl et al., 2016). Schiechl and colleagues depleted
CD4+ T cells in this model of cardiac fibrosis as a way to discard the
IL-4 produced by lymphocytes and still observed development of fibro-
sis, possibly through basophil-produced IL-4. However, eosinophils are
also known to produce this cytokine; therefore it is possible that in
this model basophils alone or in combination with eosinophils were
responsible for the development of fibrosis (Voehringer et al., 2004).
This means that basophils may contribute to the fibrotic process, but
further investigation is required.
To the best of our knowledge there is no evidence pointing at
a role for basophils in the pathogenesis of either pulmonary fibro-
sis or more general fibrotic processes. A short report from 1987
mentions the presence of “basophilic cells” in the lavage fluid of
lungs of IPF patients (Shindoh, Tanno, Ida, & Takishima, 1987). How-
ever, the “basophilic cells” referred to in this report were cells that
were positive for basophilic intracellular granules, which could also
apply to mast cells. Therefore it is not clear whether this study
actually described basophils. In fact, the role of basophils in many
functions and dysfunctions is still unknown because of their low
frequency in blood and the absence of basophilic cell lines for exper-
imentation (Karasuyama & Yamanishi, 2014). Research on basophils
has also been affected by studies into their granulocyte fellow mast
cells. Basophils and mast cells share morphological and functional
features, but due to the scarcity of basophils in blood more expen-
sive and time-consuming isolation techniques are required, making
mast cells easier to study (Chirumbolo, 2012; Crivellato, Nico, &
Ribatti, 2011; Karasuyama & Yamanishi, 2014; Warner & Kroegel,
1994).
To conclude, it is still unclear what the level of involvement of
basophils in wound repair is and there is not enough evidence point-
ing at an involvement in fibrosis in general or more particularly in the
lung.
4 WOUND HEALING IN THE AGEING LUNG
Ageing is the process of living organisms changing over time due to
internal and external forces that affect the state of their systems and
organs. These changes lead to a gradual decline in body functions and
commonly lead to diseases. In the lung, pulmonary fibrosis and COPD
are two common age-related diseases as their onset usually presents
aftermiddle age (Rojas et al., 2015). Althoughage is a knownrisk factor,
it is not clear how it affects the pathogenesis of fibrotic diseases such
as pulmonary fibrosis. The general hypothesis is that fibrosis devel-
ops after persistent low-grade inflammation, possibly due to repeti-
tive exposure to an insult, causing continuous tissue damage. The body
attempts to fix the damage with deposition of excessive ECM, which
actually remodels the tissue to an extent that its architecture and its
function become impaired. However, most of the mouse studies used
to formulate this hypothesis have been performed using young animals
and it is not known how fibrosis develops in an ageing immune sys-
tem.Nonetheless, analyzing evidence on how the aged immune system
responds toother conditions couldhelp usunderstandwhat is hamper-
ing tissue repair and promoting development of fibrosis in the ageing
lung.
It is well known that the immune system changes with age and
there is evidence that this phenomenon known as “immunosenes-
cence” is contributing to the development of age-related diseases,
including pulmonary fibrosis (Boe et al., 2016; Chilosi, Carloni, Rossi,
& Poletti, 2013; Frasca & Blomberg, 2016). One of the best-known
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characteristics of an aged immune system is the low-grade chronic pro-
inflammatory state known as “inflammageing” (Frasca & Blomberg,
2016). This state is associated with production of high levels of pro-
inflammatory cytokines (i.e., IL-1𝛽 , IL-6, TNF-𝛼) that are thought to
contribute to many diseases and to mortality in the elderly popu-
lation (Boe et al., 2016). Senescence is another important player in
age-related diseases and it has been postulated that premature age-
ing and cellular senescence are features of pulmonary fibrosis (Chilosi
et al., 2013). Interestingly, it was reported that senescence-associated
changes in lung tissue begin to appear already in middle age (Calvi
et al., 2011). Calvi et al. showed in a longitudinal study of ageingmurine
lungs that the development of airspace enlargement, an age-related
feature, is marked by an increase in oxidative stress, cell death, and
elastase activation (Calvi et al., 2011). This profile imposes stress on
the tissue which is followed by an immune response characterized
by B-cell activation, immunoglobulin deposition, and the infiltration
of macrophages. This suggests that changes in the immune system
and lung homeostasis might precede the development of age-related
diseases, although the cause and origin of these changes are still
unknown.
With respect to innate immune cell alterations, the most relevant
for the lung are changes to neutrophils, monocytes, and macrophages
(Boe et al., 2016; Paxson et al., 2011). Neutrophils of older individuals
may either have impairedmigration or show a highly reactive response
(Boe et al., 2016). Upon cigarette smoke exposure, for instance, aged
mice have significantly higher lung infiltration of neutrophils, which is
accompanied by increased levels of keratinocyte-derived chemokine
and CXCL2 in comparison to young mice (Moriyama et al., 2010). As
mentioned earlier, neutrophilia could contribute to the development
of pulmonary fibrosis.
Ageing was also found to be associated with phenotypic and func-
tional changes in human monocytes (Merino et al., 2011; Hearps
et al., 2012). Hearps and colleagues performed a cross-sectional study
with 146 healthy individuals and they found that age was associated
with a higher proportion of intermediate CD14+CD16+ and non-
classical CD14+CD16++ monocytes (Hearps et al., 2012). Moreover,
they found that all monocyte subsets from older individuals exhibited
shorter telomeres, higher intracellular TNF-𝛼 levels at baseline and
after LPS stimulation (except for the classical subset), and impaired
phagocytosis compared to young individuals. An in vitro study by
Merinoandcolleaguesevaluated the functional andphenotypical char-
acteristics of the intermediate monocyte subset that was obtained
by culturing human classical CD14++CD16− monocytes in the pres-
ence of GM-CSF, IL-4, and IL-10 (Merino et al., 2011). They found
that intermediate CD14+CD16+ monocytes, compared to the classi-
cal CD14++CD16− subset, have a senescent phenotype (i.e., higher
counts and levels of 𝛽-galactosidase) and a higher pro-inflammatory
activity in terms of chemokine receptor expression (i.e., CCR5, CCR7,
CX3CR1) andadhesion toendothelial cells. Together these studies sug-
gest that the proportion of the intermediate CD14+CD16+monocyte
subset is higher with older age and that this subset is characterized by
a senescent and pro-inflammatory phenotype. Therefore their accu-
mulation in older individuals could be contributing to chronic inflam-
mation and possibly to inflammatory diseases. Additionally, Suchy
and colleagues showed that LPS stimulation of monocyte-derived
macrophages from young healthy individuals resulted in expression
of both classical activation markers (i.e., nitric oxide and reactive
oxygen species) and alternative activation markers (i.e., suppres-
sor of cytokine signaling 1 and arginase-1) (Suchy, Łabuzek, Bułdak,
Szkudłapski, &Okopień, 2014). Conversely, in elderly healthy individu-
als only the classical activation markers were present, suggesting that
monocyte-derived macrophages of young individuals are more capa-
ble of eliciting a balanced response to inflammatory stimuli than the
elderly.
Alveolar macrophages are also affected by ageing. For instance,
they were shown to have decreased efferocytosis (phagocytosis of
apoptotic cells), which can lead to a prolongation and spreading of
inflammation (Aprahamian, Takemura, Goukassian, & Walsh, 2008;
Arnardottir, Dalli, Colas, Shinohara, & Serhan, 2014). Moreover, alve-
olar macrophages from old mice were found to produce lower levels
inflammatory cytokines (i.e., TNF-𝛼 and IL-6) in response to stimuli,
which was also observed in splenic macrophages of old mice (Gomez,
Goral, Ramirez, Kopf, & Kovacs, 2006; Hinojosa, Boyd, & Orihuela,
2009; Linton&Dorshkind, 2004;Murciano, Yáñez,O'Connor, Gozalbo,
&Gil, 2008; Ren et al., 2009). It has been suggested that the high levels
of pro-inflammatory cytokines that characterize “inflammageing” are
constantly activating macrophages to a point where further stimula-
tion with PAMPs or other relevant stimuli is not achieved and proper
responses to these stimuli is not possible anymore (Kovacs, Grabowski,
Duffner, Plackett, & Gregory, 2002).
In addition to changes in immune cells, the overall regenerative
capability has been shown to decrease with ageing. A study by Pax-
son and colleagues evaluated the regenerative ability of the lungs after
pneumonectomy in young (3 months), middle-aged (9 months), and
old mice (24 months). They found that young mice were able to fully
restore the lung volume and alveolar surface by day 21, while the
middle-aged mice showed a limited recovery in the same time and the
old mice had a total lack of recovery (Paxson et al., 2011). The authors
found significantly lower baseline numbers of type 2 alveolar epithelial
cells (AECII) in older mice and even lower numbers after pneumonec-
tomy, compared to the young mice. Since AECII are progenitor cells
for the pneumocytes lining the alveoli, a decrease in AECII denotes a
lower alveolar regenerative capacity after injury. Additionally, various
growth factors are expressed at lower levelswith age (i.e., VEGF, PDGF,
epidermal growth factor [EGF]), which could contribute to a delay or a
deficiency in re-epithelialization and overall tissue regeneration (Stout
& Suttles, 2005).
Altogether, the evidence suggests that ageing entails extensive
changes in the immune system that influence inflammatory and
repair responses in the elderly lung. These changes include dys-
regulation in numbers or functions of neutrophils, monocytes, and
macrophages. Moreover, a decline in the proliferative and regener-
ative abilities of AECII contributes to the poor or altered healing
response in aged lungs. Table 1 summarizes the most important find-
ings reviewed in this section. It is not clear whether these immune
changes are the cause of pulmonary fibrosis, but they may contribute
to its pathogenesis and to the development of other age-related
diseases.
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TABLE 1 Features of immunosenescence in the context of myeloid cells
5 CONCLUDING REMARKS
Altogether the evidence shows that myeloid cells are not only leading
players in tissue repair, but they are also tightly associated with the
development of fibrosis in the lung. The evidence connecting myeloid
cells with fibrosis development is strong for neutrophils, monocytes,
macrophages, and fibrocytes in particular.
The dynamics of the innate immune system in the fibrotic lung
suggests that fibrosis develops as an exaggerated repair phenotype
following injury with continuous feedback loops among cells and a
poorly balanced response leading to chronic progressive disease. Due
to their common background, fibrosis and tissue repair share charac-
teristic cellular markers, although these two processes are not equal.
For instance, fibroblasts and macrophages may present a very similar
phenotype during tissue repair and in fibrosis (i.e., myofibroblast acti-
vation andM2polarization, respectively), andmediators such as TGF-𝛽
and IL-4 are present in both conditions. However, while in tissue repair
these traits are transitory, in fibrosis they persist. Even if these phe-
notypes can point to the development of fibrosis, other characteris-
tics should be taken into consideration for the accurate assessment of
fibrosis development. So, when is it accurate to call it fibrosis andwhen
is it simply a repair response? In animalmodels and in patientswith pul-
monary fibrosis it is possible to identify fibrosis through physiological
and histological characteristics, such as excess ECM deposition, alter-
ations in lung architecture, the formation of fibroblast foci, and a poor
or absent pro-inflammatory aspect. However, some of these features
are more difficult to reproduce during in vitro studies, as thesemodels
cannot represent all the possible variables found in vivo. It is therefore
of importance to keep this in mind when interpreting in vitro experi-
ments, since what one could consider as a fibrotic response could sim-
ply be the activation of a repair response. The use of patient sam-
ples, human and animal precision-cut tissue slices, and animal models
can provide more accurate information about the dynamics of fibrosis
development.
The inflammatory phase is not considered to play an important
role in the pathogenesis of fibrosis, or at least not during advanced
stages of the disease. This has been suggested by the observation
that using corticosteroids for treating fibrosis can be detrimental
for patients (Fujimoto, Kobayashi, & Azuma, 2015). The study from
Gibbons and colleagues suggests that the undesirable effects of cor-
ticosteroid treatment could be due to a boost ofM2macrophages that
are directly associated with the development of pulmonary fibrosis
(Gibbons et al., 2011). In this scenario, although a pro-inflammatory
profile is inhibited by this treatment, the induction of M2 polarization
may stimulate fibrosis development. We also showed this in a model
for liver fibrosis, in which Kupffer-cell-specific delivery of the corticos-
teroid dexamethasone during induction of liver fibrosis exacerbated
the deposition of ECM in the liver (Melgert et al., 2001). Neverthe-
less, the evidence included here shows that many cells and mediators
with pro-inflammatory activity positively correlate with fibrosis devel-
opment. This pro-inflammatory activity may actually be important for
resolution of an injury and be a desperate attempt of the system to
resolve and its failure to do so, thus correlatingwith the severity of the
fibrotic process. In this case, the worsening or lack of improvement in
patients with pulmonary fibrosis upon anti-inflammatory treatments
could be due to a decrease in the attempt to resolve the fibrosis. It still
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remains to be elucidatedwhether particular polarization stages of pro-
inflammatory cells, such as N1 or N2 neutrophils, are predominantly
present in fibrosis.
The evidence supporting the essential role of innate immune cells in
the development of fibrosis is currently leading to therapeutic devel-
opments targeting myeloid cells. For instance, an anti-galectin-3 drug
called TD139 is going to enter a phase IIB trial (Hirani, Nicol, &
MacKinnon, 2017). Galectin-3 is a 𝛽-galactoside-binding lectin crucial
for macrophage M2 polarization and was found to be expressed more
in alveolar macrophages of IPF patients compared to those of control
subjects (Mackinnon et al., 2008; Nishi et al., 2007). Prevention of M2
polarization through inhibiting galectin-3 may inhibit fibrosis develop-
ment as thesemacrophages are strongly associatedwith fibrosis devel-
opment (Mackinnon et al., 2008).
The study of smaller animals like salamanders may also help with
finding alternative therapeutic strategies against the development of
fibrosis, as these amphibians have the ability of scar-free repair with
full tissue regeneration after tissue damage. Interestingly, the study by
Godwin and colleagues shows that, although many features of inflam-
mation of the salamander resemble those of mammals, these amphib-
ians present a more dynamic response to injury with a simultaneous
induction of the inflammatory and the anti-inflammatory phases in
the first 24 h (Godwin et al., 2013). Identification of similarities and
differences between the amphibian and mammalian response to tis-
sue injury may provide targets for fibrosis regulation. It is already
known that one of the differences between salamanders and mam-
mals is the fact that salamanders lack adaptive immunity. It has been
suggested that this contributes to fibrosis development but it is still
unclear how. It is possible that the cells of the adaptive immunity are
involved in an autoimmune-like response against lung antigens, trig-
gered by repetitive tissue damage. In fact, features of autoimmunity
have been described for IPF and are thought to contribute to IPF exac-
erbation, since autoantibody-reductive therapies have been shown to
improve the lung function of IPF patients during acute exacerbation
(Donahoe et al., 2015). These and other studies have shown that
there are indeed alterations in the adaptive immune system of pul-
monary fibrosis patients compared to healthy individuals (Duncan,
2014). Nonetheless, the evidence included here also shows that innate
immunity (i.e., myeloid cells) is key in the development of fibrosis.
Therefore, it is of interest for future studies to elucidate the interaction
between the innate and the adaptive immune system and to find the
dysfunctional connection between these two parts that leads to this
pathological condition in humans.
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